Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Asthma

Asthma

Recruiting

Assessing rocatinlimab in moderate-to-severe asthma

The purpose of this study is to investigate whether rocatinlimab is safe and effective in reducing asthma symptoms (such as an asthma exacerbation, also known as an asthma attack) and improving lung function, as well as whether it causes any side effects.

Status
Recruiting
Principal Investigator
Céline Bergeron
Body Locations and Systems
Lungs and Breathing
Asthma
Age
19-75

Assessing the effect of dexpramipexole in people with severe eosinophilic asthma

The purpose of this study is to investigate the safety, tolerability and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.

Status
Recruiting
Principal Investigator
Céline Bergeron
Body Locations and Systems
Lungs and Breathing
Asthma
Age
19 and above

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

The purpose of this study is to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.

Status
Recruiting
Principal Investigator
Céline Bergeron
Body Locations and Systems
Lungs and Breathing
Asthma
Area
Vancouver
Age
12-80

Closed for Recruitment

Assessing the effect of dexpramipexole in people with eosinophilic asthma

The purpose of this study is to evaluate dexpramipexole as an add-on therapy in participants with inadequately controlled eosinophilic asthma, on Global Initiative for Asthma (GINA) 2021 Step 3, 4 or 5 therapy (or GINA 2021 Step 4 or 5 therapy in Poland) to confirm improvements in lung function, asthma control and quality of life.

Status
Closed for Recruitment
Principal Investigator
Céline Bergeron
Body Locations and Systems
Lungs and Breathing
Asthma
Age
19 and above

Assessing the efficacy of rilzabrutinib in adults with moderate-to-severe asthma

The purpose of this study is to evaluate the safety, tolerability and effectiveness of rilzabrutinib (also known as SAR444671) compared to a placebo in adults with moderate-to-severe asthma.

Status
Closed for Recruitment
Principal Investigator
Céline Bergeron
Body Locations and Systems
Lungs and Breathing
Asthma
Age
18-70

Canadian Asthma Text Messaging Study

The purpose of this study is to understand asthmatic patients' knowledge, perceptions and viewpoints about using a telehealth approach to manage their asthma conditions.

Status
Closed for Recruitment
Body Locations and Systems
Lungs and Breathing
Asthma
Age
21 and above

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

The purpose of this study is to test the safety and efficacy of an inhaled medication (CSJ117) compared with a placebo for improving lung function in patients with inadequate control of moderate to severe asthma.

Status
Closed for Recruitment
Principal Investigator
Céline Bergeron
Body Locations and Systems
Asthma
Area
Vancouver
Age
18 - 75

Care during COVID-19 survey

The purpose of this study is to understand how patients with asthma and COPD have been affected by the changes to the health care system as a result of the COVID-19 pandemic.

Status
Closed for Recruitment
Principal Investigator
Christopher Carlsten
Body Locations and Systems
Asthma
COPD
Area
Vancouver
Age
18 and above

Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics (ARIA)

This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
18-65

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

The purpose of this study is to evaluate the long-term safety, efficacy and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma study.

 

 

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
12 and above

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe asthma).

Recruitment poster

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
12 and above

Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (MESOS)

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled Corticosteroid.
 

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
18-75

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066 as compared to placebo over a 24-week treatment period in severe asthma patients. The primary endpoint is time to first asthma worsening during the planned 24 week treatment period for active vs. placebo treated patients on top of standard of care therapy. Upon demonstration of a meaningful clinical response, another important objective is the identification of biomarkers that can be used to target patients who will likely respond to treatment with BI 655066.
 

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
18-75

Evaluation of Dupilumab in Patients With Persistent Asthma

Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893 [REGN668]) in patients with persistent asthma.

Secondary Objectives:

To evaluate the safety and tolerability of dupilumab. To evaluate the effect of dupilumab in improving patient-reported outcomes including health-related quality of life.

To evaluate dupilumab systemic exposure and incidence of antidrug antibodies.

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
12 and above

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

Prospective, single-arm, longitudinal, international, multicentre study in a real-world cohort of adult severe asthma participants being conducted to assess the relationships between asthma biomarkers and asthma-related health-outcomes for a period of 52 weeks.

Recruitment poster

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
18 and above

Asthma Self-management Via Application of Telehealth (asthma)

The disease being studied is asthma. The main objective of this study is to assess the feasibility of the recruitment goals and also the logistical issues related to use of tele-health technology in developing electronic asthma action plan (eAAP) and communicate with asthma patients in a time period of 24 months. The goals are: 1) enable asthma patients to self-manage their asthma symptoms. The secondary, 2) help care providers to intervene appropriately based on the patient's health status.

Status
Closed for Recruitment
Body Locations and Systems
Asthma
Area
Vancouver
Age
19-85
Subscribe to Asthma

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy